THE TGA has approved Mounjaro (tirzepatide), a drug used for type 2 diabetes and obesity, to also treat moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity. OSA affects 780,000 Australians and is linked to serious health risks. Mounjaro works by promoting weight loss, reducing airway blockages. It’s the first approved medicine for OSA in Australia, offering an alternative to CPAP machines and surgery. Experts hail it as a major breakthrough for sleep and obesity-related health care.
APPROVAL FOR SLEEP APNOEA DRUG
-
font size
decrease font size
increase font size
editor
Publisher
Michael Walls
michael@accessnews.com.au
0407 783 413
